Current and future use of favipiravir in patients with COVID-19
There are experimental and clinical data regarding the activity of favipiravir against the SARS-CoV-2 virus. The is evidence of significant variability in pharmacokinetics and associated achievement of the required inhibitory concentration of the drug. The evidence base for the effectiveness of use...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
Izdatelstvo OKI
2020-10-01
|
| Col·lecció: | Качественная клиническая практика |
| Matèries: | |
| Accés en línia: | https://www.clinvest.ru/jour/article/view/540 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|